



**Consolidated Financial Statements for the Third Quarter Ended December 31, 2020  
FY2021 (April 1, 2020 - March 31, 2021) [UNAUDITED]**

February 10, 2021

Company name:	Takara Bio Inc.
Stock exchange listings:	Tokyo Stock Exchange (1st section)
Code number:	4974
URL:	<a href="https://www.takara-bio.co.jp">https://www.takara-bio.co.jp</a>
Company representative:	Koichi Nakao, President
Contact:	Takuya Kakemi, General Manager of Corporate Management Division, Executive Officer Tel. (077) 565-6970
Scheduled date of quarterly statement filing:	February 12, 2021
Scheduled date of starting delivery of dividends:	—
Supplementary documents of the financial results:	Yes
Financial results information meeting:	No

Notes: 1. The accompanying financial statements have been prepared in accordance with accounting principles and practices generally accepted in Japan.  
2. Amounts are rounded down to the nearest million yen.

**1. Results for the nine months ended December 31, 2020 (Apr. 1, 2020 – Dec. 31, 2020)**

**(1) Consolidated operating results**

	(Percentages indicate changes from the same period of the previous fiscal year.)			
	Nine months ended Dec. 31, 2020		Nine months ended Dec. 31, 2019	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	29,549	20.3	24,558	(5.1)
Operating profit	8,791	126.6	3,879	13.0
Ordinary profit	8,919	128.9	3,896	9.8
Net income (loss) attributable to owners of parent	5,726	111.4	2,708	29.7
Net income per share (in yen)	47.56		22.49	
Fully diluted net income per share (in yen)	—		—	
(Note) Comprehensive income	4,940	226.6	1,512	(14.8)

**(2) Consolidated financial position**

	As of Dec. 31, 2020	As of Mar. 31, 2020
	(Millions of yen)	(Millions of yen)
Total assets	83,846	75,009
Net assets	70,568	66,591
Equity ratio (%)	84.0	88.7
Net assets per share (in yen)	585.12	552.23
(Reference) Equity	70,457	66,496

**2. Dividends**

	Annual dividends per share in yen		
	Year ended Mar. 31, 2020	Year ending Mar. 31, 2021	Year ending Mar. 31, 2021 (Forecast)
First quarter end	—	—	
Second quarter end	0.00	0.00	
Third quarter end	—	—	
Year end	8.00		14.00
Annual	8.00		14.00

(Note) Revision of dividend payment forecast since the most recently announced payment forecast: Yes

The original disclosure in Japanese was released on February 10, 2021 at 15:00 (GMT+8)

### 3. Forecast for the year ending March 31, 2021 (Apr. 1, 2020 – Mar. 31, 2021)

(Percentages indicated changes from the same period of the previous fiscal year.)

	Year ending Mar. 31, 2021	
	(Millions of yen)	(%)
Net sales	45,200	30.8
Operating profit	12,000	91.2
Ordinary profit	12,100	90.6
Net income attributable to owners of the parent	7,800	104.2
Net income per share (in yen)	64.78	

(Note) Revision of financial forecast since the most recently announced payment forecast: Yes

#### ※ Others

(1) Changes in subsidiaries during the nine months ended December 31, 2020

(Changes in specified subsidiaries resulting in change of scope) : No

Newly included: – (Name)

Excluded: – (Name)

(2) Application of special accounting methods to the consolidated quarterly financial statements: No

(3) Changes in accounting policies, changes in accounting estimates, and retrospective restatement

1) Changes based on revisions of accounting standard: No

2) Changes other than ones based on revisions of accounting standard: No

3) Changes in accounting estimates: No

4) Restatement: No

(4) Number of outstanding shares (Common stock)

1) Number of outstanding shares at year end (Treasury stocks are included)

As of December 31, 2020 120,415,600

As of March 31, 2020 120,415,600

2) Number of treasury stocks at year end

As of December 31, 2020 –

As of March 31, 2020 –

3) Average number of outstanding shares

As of December 31, 2020 120,415,600

As of December 31, 2019 120,415,600

※ These financial statements are not subject to auditing.

※ Comment regarding appropriate use of earnings forecasts and other special notes

Forward-looking statements contained in this document are determined by the Takara Bio Company based on information currently available to the Company and include a number of uncertainties. Actual results could differ from these forecasts due to changes in conditions that occur in the future. For information regarding the above, please refer to 1. Qualitative Information for the nine months ended December 31, 2020 (4) Qualitative Information Regarding Consolidated Forecasts, on page 2 of the attached document.

Contents of the attached document

1. Qualitative Information for the nine months ended December 31, 2020.....	2
(1) Overview of Financial Results.....	2
(2) Overview of Financial Position.....	2
(3) Overview of Cash Flows.....	2
(4) Qualitative Information Regarding Consolidated Forecasts.....	2
2. Consolidated Quarterly Financial Statements and Primary Notes.....	3
(1) Consolidated Quarterly Balance Sheets.....	3
(2) Consolidated Quarterly Statements of Profit or Loss and Consolidated Quarterly Statements of Comprehensive Income.....	5
(Consolidated Quarterly Statements of Profit or Loss)	
(For the nine months ended December 31, 2020) .....	5
(Consolidated Quarterly Statements of Comprehensive Income)	
(For the nine months ended December 31, 2020) .....	6
(3) Consolidated Quarterly Statements of Cash Flows.....	7
(4) Notes to Consolidated Quarterly Financial Statements.....	8
(Notes on Premise of Going Concern) .....	8
(Notes in case of Changes in Marked Amount of Shareholders' Equity) .....	8
(Additional Information).....	8
(Segment Information).....	8
3. Supplementary Information .....	9
(1) Trends in Key Management Indicators.....	9
(2) Comparative Consolidated Statement of Profit or Loss .....	10
(3) Comparative Statement of Profit Relating to Consolidated Earnings Forecast.....	11

## 1. Qualitative Information for the nine months ended December 31, 2020

### (1) Overview of Financial Results

In the fiscal year under review, ended December 31, 2020, the global economy has continued to be uncertain due to the influence of the new Coronavirus disease (COVID-19) pandemic, the trade friction issue in the US and China, and Brexit, etc.

Against these circumstances, under our corporate philosophy of “Contributing to the health of humankind through the development of revolutionary biotechnologies such as gene therapy”, Takara Bio (the Company) is promoting the development of bio-drug discovery platform technologies through the businesses of research reagents and scientific instruments and CDMO business, aiming to become a drug discovery company and continuously creates new modalities in line with “Long-Term Management Plan FY2026” and “Medium-Term Management Plan FY2023”. Amid the worldwide expansion of COVID-19, the Company prioritized the stable supply of PCR testing-related products, and the establishment of a manufacturing system for generative medicine products including vaccine, for which social demands are high.

Overall net sales in the third quarter of the current fiscal year, although sales of Gene Therapy decreased year on year, sales of research reagents and contract services increased year on year. In addition, sales of PCR testing-related products, including in vitro diagnostics for detecting the new coronavirus launched in November, increased. As a result, net sales increased 20.3% to ¥29,549 million. Cost of sales decreased 15.0% year on year to ¥8,297 million due to the change of sales composition by item and others, and an increase in production utilization rates, and gross profit increased 43.7% year on year to ¥21,251 million. Selling, general and administrative (SG&A) expenses increased 14.2% year on year to ¥12,460 million due to the increase in R&D expenses, etc., and the Company recorded operating profit up 126.6% year on year to ¥8,791 million.

Accompanied with the increase in operating profit, ordinary profit increased 128.9% to ¥8,919 million, profit before income taxes and others increased 115.3% year on year to ¥8,359 million, and net income attributable to owners of parent increased 111.4% year on year to ¥5,726 million.

Segment information has been omitted because the reportable segments were changed to a single segment from the three months ended June 30, 2020. For details, please refer to “2. Consolidated Quarterly Financial Statements and Primary Notes (Segment Information)”.

Sales of in vitro diagnostics sold from the third quarter of current fiscal year has been classified as research reagents.

### (2) Overview of Financial Position

In the third quarter of the current fiscal year, total assets were ¥83,846 million, an increase of ¥8,836 million compared with that at the end of the previous fiscal year. This primarily resulted from an increase in non-current assets by ¥5,354 million based on the acquisition of land and building for the new facility of Takara Bio USA, Inc. and the Company’s manufacturing facility, etc.

Total liabilities were ¥13,277 million, an increase of ¥4,859 million compared with that at the end of the previous fiscal year. This primarily resulted from increases of ¥3,349 million in others for current liabilities and ¥1,062 million in accrued income taxes.

Total net assets stood at ¥70,568 million, an increase of ¥3,976 million compared with that at the end of the previous fiscal year. The main factor was an increase of ¥4,763 million in retained earnings and a decrease of ¥827 million in foreign currency translation adjustment due to the appreciation of the yen.

### (3) Overview of Cash Flows

Net cash provided by operating activities was ¥7,978 million, up by ¥3,290 million compared with the same period of the previous fiscal year. This was mainly due to cash inflow of profit before income taxes and others of ¥8,359 million, depreciation and amortization of ¥2,421 million, ¥1,567 million from an increase in current liabilities, and cash outflow of an increase of ¥2,242 million in trade receivables and ¥2,003 million from an increase in inventories.

Net cash provided by investing activities was ¥1,675 million, a decrease of ¥905 million compared with the same period of the previous fiscal year. This was primarily due to ¥6,994 million in payments for purchase of property, plant and equipment and intangible assets, ¥2,082 million in subsidies received, and ¥2,000 million in proceeds from sales and redemption of securities.

Net cash used in financing activities was ¥1,068 million, an increase of ¥138 million compared with the same period of the previous fiscal year. This was primarily because of cash dividends paid of ¥962 million.

As a result of the above, balance of cash and cash equivalents at the end of third quarter of the current fiscal year, including the effect of exchange rate change on cash and cash equivalents, stood at ¥19,467 million, up by ¥5,004 million from the previous fiscal year-end.

### (4) Qualitative Information Regarding Consolidated Forecasts

The Company has revised the financial forecast and the dividend forecast disclosed on November 10, 2020. For details, refer to “Notice Regarding Forecast Revisions of Financial results and Dividend (Dividend Increase)” disclosed on February 10, 2021.

For comparison between revised forecast for consolidated results, previous period results, and previous forecast, refer to “Comparative Statement of Profit Relating to Consolidated Earnings Forecasts” on page 11.

The original disclosure in Japanese was released on February 10, 2021 at 15:00 (GMT+8)

## 2. Consolidated Quarterly Financial Statements and Primary Notes

### (1) Consolidated Quarterly Balance Sheets

(Millions of yen)

	As of Mar. 31, 2020	As of Dec. 31, 2020
<b>Assets</b>		
Current assets		
Cash and deposits	18,266	21,856
Notes and accounts receivable-trade	9,102	11,283
Marketable securities	2,000	—
Merchandise and finished goods	4,511	4,994
Work in process	1,208	1,748
Raw materials and supplies	1,874	2,656
Other	1,479	778
Allowance for doubtful accounts	(56)	(54)
Total current assets	38,387	43,263
Non-current assets		
Property, plant and equipment		
Buildings and structures	16,478	15,495
Accumulated depreciation	(5,630)	(4,933)
Buildings and structures, net	10,847	10,562
Machinery, equipment and vehicles	6,705	6,977
Accumulated depreciation	(3,353)	(3,665)
Machinery, equipment and vehicles, net	3,352	3,311
Tools, furniture and fixtures	7,912	7,857
Accumulated depreciation	(5,217)	(5,284)
Tools, furniture and fixtures, net	2,694	2,573
Land	5,724	8,195
Construction in progress	85	3,521
Others	1,635	1,639
Accumulated depreciation	(126)	(235)
Others, net	1,509	1,404
Total Property, plant and equipment	24,213	29,568
Intangible assets		
Goodwill	7,006	6,406
Other	4,348	3,376
Total intangible assets	11,355	9,782
Investments and other assets		
Investments and other assets	1,053	1,231
Total investments and other assets	1,053	1,231
Total non-current assets	36,622	40,582
<b>Total assets</b>	<b>75,009</b>	<b>83,846</b>

The original disclosure in Japanese was released on February 10, 2021 at 15:00 (GMT+8)

(Millions of yen)

	As of Mar. 31, 2020	As of Dec. 31, 2020
<b>Liabilities</b>		
Current liabilities		
Notes and accounts payable-trade	1,027	1,464
Accrued income taxes	683	1,746
Provision	557	622
Other	3,978	7,328
Total current liabilities	6,248	11,161
Non-current liabilities		
Retirement benefit liabilities	783	789
Other	1,386	1,326
Total non-current liabilities	2,169	2,115
Total liabilities	8,418	13,277
<b>Net assets</b>		
Shareholders' equity		
Share capital	14,965	14,965
Capital surplus	32,893	32,893
Retained earnings	18,501	23,265
Total shareholders' equity	66,360	71,124
Accumulated other comprehensive income		
Foreign currency translation adjustment	436	(391)
Remeasurements of retirement benefit	(300)	(275)
Total accumulated other comprehensive income	135	(667)
Non-controlling interests	95	111
Total net assets	66,591	70,568
<b>Total liabilities and net assets</b>	<b>75,009</b>	<b>83,846</b>

The original disclosure in Japanese was released on February 10, 2021 at 15:00 (GMT+8)

**(2) Consolidated Quarterly Statements of Profit or Loss and Consolidated Quarterly Statements of Comprehensive Income  
(Consolidated Quarterly Statements of Profit or Loss)**

**(For the nine months ended December 31, 2020)**

(Millions of yen)

	Nine months ended Dec. 31, 2019	Nine months ended Dec. 31, 2020
Net sales	24,558	29,549
Cost of sales	9,767	8,297
Gross profit	14,791	21,251
SG&A expenses		
Employees' salaries and bonuses	3,045	3,313
Retirement benefit expenses	128	145
R&D expenses	2,812	3,656
Provision for doubtful accounts and bonuses	224	305
Other	4,701	5,039
Total SG&A expenses	10,911	12,460
Operating profit	3,879	8,791
Non-operating profit		
Interest income	98	85
Foreign exchange gains	—	3
Rent income from real estate	82	93
Other	32	23
Total non-operating profit	212	205
Non-operating expenses		
Interest expenses	2	18
Foreign exchange loss	153	—
Rent expenses on real estate	26	38
Expenses of inactive non-current assets	4	16
Other	8	2
Total non-operating expenses	195	77
Ordinary profit	3,896	8,919
Extraordinary profit		
Gain on sale of fixed assets	0	1
National subsidies	—	35
Total extraordinary profit	0	36
Extraordinary losses		
Loss on sale and retirement of fixed assets	11	49
Loss on business liquidation	—	462
Loss on tax purpose reduction entry of non-current assets	—	35
Loss on sale of investment securities	2	—
Other	—	49
Total extraordinary losses	13	596
Profit before income taxes and others	3,883	8,359
Income taxes-current	935	2,693
Income taxes-deferred	229	(83)
Total income taxes	1,165	2,610
Net income	2,717	5,749
Net income attributable to non-controlling interest	8	22
Net income attributable to owners of the parent	2,708	5,726

The original disclosure in Japanese was released on February 10, 2021 at 15:00 (GMT+8)

**(Consolidated Quarterly Statements of Comprehensive Income)**

**(For the nine months ended December 31, 2020)**

	(Millions of yen)	
	Nine months ended Dec. 31, 2019	Nine months ended Dec. 31, 2020
Net income	2,717	5,749
Other comprehensive income		
Foreign currency translation adjustment	(1,222)	(834)
Remeasurements of retirement benefit	18	25
Total other comprehensive income	(1,204)	(809)
Comprehensive income	1,512	4,940
Comprehensive income attributable to:		
Owners of the parent	1,506	4,923
Non-controlling interest	5	16



The original disclosure in Japanese was released on February 10, 2021 at 15:00 (GMT+8)

**(3) Consolidated Quarterly Statements of Cash Flows**

(Millions of yen)

	Nine months ended Dec. 31, 2019	Nine months ended Dec. 31, 2020
<b>Net cash provided by (used in) operating activities</b>		
Profit before income taxes and others	3,883	8,359
Depreciation and amortization	2,102	2,421
Depreciation and amortization on other	89	61
Amortization of goodwill	372	367
Increase (decrease) in allowance for doubtful accounts	3	(1)
Increase (decrease) in other provision	(133)	68
Increase (decrease) in retirement benefit liabilities	30	5
Interest income	(98)	(85)
Interest expenses	2	18
Loss (gain) on sale and retirement of fixed assets	11	48
Loss on business liquidation	—	462
Decrease (increase) in trade receivables	1,686	(2,242)
Decrease (increase) in inventories	(1,201)	(2,003)
Increase (decrease) in notes and accounts payable-trade	(382)	450
Increase (decrease) in other current liabilities	(1,039)	1,567
Other	233	(26)
Subtotal	5,560	9,473
Interest and dividend income received	98	86
Income expenses paid	(2)	(18)
Income taxes paid	(968)	(1,563)
Net cash provided by (used in) operating activities	4,688	7,978
<b>Net cash provided by (used in) investing activities</b>		
Payments into time deposits	(4,964)	(2,038)
Proceeds from withdrawal of time deposits	5,352	3,422
Purchase of marketable securities	(2,000)	—
Proceeds from sale and redemption of marketable securities	2,000	2,000
Purchase of property, plant and equipment and intangible assets	(3,011)	(6,994)
Proceeds from sales of property, plant and equipment and intangible assets	99	14
Purchase of other depreciable assets	(57)	(159)
Subsidies received	—	2,082
Other	(0)	(2)
Net cash provided by (used in) investing activities	(2,581)	(1,675)
<b>Net cash provided by (used in) financing activities</b>		
Dividends paid	(841)	(962)
Repayments of lease obligations	(88)	(105)
Net cash provided by (used in) financing activities	(929)	(1,068)
Effect of exchange rate change on cash and cash equivalents	(399)	(230)
Net increase (decrease) in cash and cash equivalents	777	5,004
Cash and cash equivalents at beginning of period	9,464	14,462
Cash and cash equivalents at end of period	10,241	19,467

The original disclosure in Japanese was released on February 10, 2021 at 15:00 (GMT+8)

**(4) Notes to Consolidated Quarterly Financial Statements**

**(Notes on Premise of Going Concern)**

No items to report.

**(Notes in case of Changes in Marked Amount of Shareholders' Equity)**

No items to report

**(Additional Information)**

(Accounting Estimates for the COVID-19 Pandemic)

At the end of the previous fiscal year, it was assumed that the impact of the COVID-19 on our group would recover gradually to be nearly disappeared in the second half of FY2021. However, based on information available at the time of preparation of the consolidated financial statements for the third quarter of the fiscal year under review, the Company revised the assumption that the impact will continue for a certain period of FY2022, although it varies by region. The Company made estimates and judgments regarding the impairment loss of goodwill and the recoverability of deferred tax assets at the end of the third quarter of the fiscal year under review based on revised assumptions, but no indicators of impairment have been identified for goodwill, and the Company has determined that no additional valuation allowance is required for the recoverability of deferred tax funds.

Due to the high degree of uncertainty associated with the impact of the COVID-19, any change in the above assumptions could have an impact on the Group's financial condition and results of operations.

**(Segment Information)**

**【Segment Information】**

I Equivalent period of previous fiscal year (From Apr. 1, 2019 to Dec. 31, 2019)

It is described in II the nine months ended December 31, 2020 (Matters related to changes and others by reportable segment).

II Nine months ended December 31, 2020 (From Apr. 1, 2020 to Dec. 31, 2020)

This information is omitted because the Company consists of a single segment.

(Matters related to changes and others by reportable segment)

Each business division established for products and services respectively has formulated a comprehensive strategy for the products and services it handles, including its subsidiaries, and has developed its business activities. In April 2020, however, the Company decided to change the business structure with the aim of becoming a drug discovery company that creates new modalities by integrating its management resources and developing platform technology for biologics discovery.

As a result of this organizational review, the Bioindustry and Gene Therapy business segments, which were previously reported segments, have been changed to a single business segment from the first quarter of the fiscal year under review, and as a result, the reportable segments have become a single segment.

Due to this change, segment information for the third quarter of the previous fiscal year and the third quarter of the current fiscal year has been omitted.

The original disclosure in Japanese was released on February 10, 2021 at 15:00 (GMT+8)

### 3. Supplementary Information

#### (1) Trends in Key Management Indicators

##### 1). Cash Flow

(Millions of yen)

Term	Nine months ended Dec. 31, 2019 (Apr. 1, 2019 – Dec. 31, 2019)	Nine months ended Dec. 31, 2020 (Apr. 1, 2020 - Dec. 31, 2020)	Year ended Mar. 31, 2020 (Apr. 1, 2019 - Mar. 31, 2020)
Net cash provided by (used in) operating activities	4,688	7,978	6,339
Net cash provided by (used in) investing activities	(2,581)	(1,675)	(212)
Net cash provided by (used in) financing activities	(929)	(1,068)	(946)

##### 2). Net Sales by Region

(Millions of yen)

Term	Nine months ended Dec. 31, 2019 (Apr. 1, 2019 – Dec. 31, 2019)	Nine months ended Dec. 31, 2020 (Apr. 1, 2020 - Dec. 31, 2020)	Year ended Mar. 31, 2020 (Apr. 1, 2019 - Mar. 31, 2020)
Japan	9,892	12,425	14,804
U.S.	6,129	5,745	8,011
China	4,642	5,542	6,391
Asia excluding Japan and China	1,393	2,709	1,877
Europe	2,311	2,547	3,207
Other	189	578	271
Total	24,558	29,549	34,565

##### 3). R&D expenses by reportable segment

Disclosure is omitted because the reportable segments have been changed to a single segment from the first quarter of the current fiscal year.

The original disclosure in Japanese was released on February 10, 2021 at 15:00 (GMT+8)

(2) Comparative Consolidated Statement of Profit or Loss

(Rounded down to one million yen)

	Nine months ended Dec. 31, 2019 Actual	Nine months ended Dec. 31, 2020 Actual	Year on year Change	Year on year Ratio
(Net Sales)				
Research reagents	18,042	22,615	4,573	125.3%
Scientific instruments	952	1,113	161	116.9%
Contract services	3,392	5,575	2,183	164.3%
Gene therapy	2,170	243	(1,927)	11.2%
<b>Total net sales</b>	<b>24,558</b>	<b>29,549</b>	<b>4,990</b>	<b>120.3%</b>
(Operating profit and Loss)				
<b>Net sales</b>	<b>24,558</b>	<b>29,549</b>	<b>4,990</b>	<b>120.3%</b>
Cost of sales	9,767	8,297	(1,469)	85.0%
Gross profits	14,791	21,251	6,460	143.7%
SG&A expenses	10,911	12,460	1,548	114.2%
Transportation expenses	332	545	212	163.9%
Advertising expenses	52	40	(11)	77.4%
Promotion expenses	434	489	54	112.7%
R&D expenses	2,812	3,656	843	130.0%
Administrative expenses, other	7,060	7,453	393	105.6%
Enterprise taxes (external standards taxation)	218	274	55	125.3%
<b>Operating profit</b>	<b>3,879</b>	<b>8,791</b>	<b>4,911</b>	<b>226.6%</b>
(Non-operating profit and Expenses)				
Non-operating profit	212	205	(6)	96.7%
Non-operating expenses	195	77	(118)	39.5%
<b>Ordinary profit</b>	<b>3,896</b>	<b>8,919</b>	<b>5,023</b>	<b>228.9%</b>
(Extraordinary profit & Losses)				
Extraordinary profit	0	36	35	7725.0%
Extraordinary losses	13	596	582	4306.9%
Profit before income taxes and others	3,883	8,359	4,476	215.3%
Income taxes	1,165	2,610	1,444	223.9%
Net Income	2,717	5,749	3,031	211.6%
Net income (loss) attributable to non-controlling interests	8	22	13	257.3%
<b>Net income attributable to owners of the parent</b>	<b>2,708</b>	<b>5,726</b>	<b>3,018</b>	<b>211.4%</b>
Depreciation and amortization (Property, plant and equipment and intangible assets)	2,102	2,421	318	115.1%
Amortization of goodwill	372	367	(5)	98.6%

※1 Net sales of research reagents include that of in vitro diagnostics, which have been sold in the third quarter of the fiscal year under review.

※2 Net sales of “Other” in the previous fiscal year were included in “Research reagents” from the first quarter of current fiscal year, and results for the third quarter of the previous fiscal year in this table have been reclassified to reflect this change.

※3 The disclosure of profit and loss by segment (operating profit) is omitted because the reporting segments were changed to a single segment from the first quarter of the current fiscal year.

The original disclosure in Japanese was released on February 10, 2021 at 15:00 (GMT+8)

**(3) Comparative Statement of Profit Relating to Consolidated Earnings Forecasts**

(Rounded down to one million yen)

	Year ended Mar. 31, 2020 Actual	Year ending Mar. 31, 2021 Previous forecast	Year ending Mar. 31, 2021 Current forecast	Year on year Change	Year on year Ratio	Previous forecast Change	Previous forecast Ratio
(Net Sales)	(Net Sales)						
Research reagents	24,840	29,940	34,014	9,173	136.9%	4,073	113.6%
Scientific instruments	1,242	1,454	1,844	601	148.4%	389	126.8%
Contract services	6,186	8,539	9,087	2,901	146.9%	548	106.4%
Gene therapy	2,295	865	253	(2,042)	11.0%	(611)	29.3%
<b>Total Net Sales</b>	<b>34,565</b>	<b>40,800</b>	<b>45,200</b>	<b>10,634</b>	<b>130.8%</b>	<b>4,400</b>	<b>110.8%</b>
(Operating profit and Loss)							
<b>Net Sales</b>	<b>34,565</b>	<b>40,800</b>	<b>45,200</b>	<b>10,634</b>	<b>130.8%</b>	<b>4,400</b>	<b>110.8%</b>
Cost of sales	13,459	15,420	15,526	2,067	115.4%	105	100.7%
Gross profits	21,105	25,379	29,673	8,567	140.6%	4,294	116.9%
SG&A expenses	14,830	17,379	17,673	2,842	119.2%	294	101.7%
Transportation expenses	492	693	725	232	147.3%	32	104.6%
Advertising expenses	73	58	57	(15)	78.4%	(1)	97.4%
Promotion expenses	579	724	726	147	125.5%	2	100.4%
R&D expenses	3,869	5,173	5,288	1,418	136.7%	115	102.2%
Administrative expenses, other	9,511	10,399	10,503	992	110.4%	103	101.0%
Enterprise taxes (external standards taxation)	305	329	371	66	121.8%	42	112.7%
<b>Operating profit</b>	<b>6,274</b>	<b>8,000</b>	<b>12,000</b>	<b>5,725</b>	<b>191.2%</b>	<b>4,000</b>	<b>150.0%</b>
(Non-operating profit and Expenses)							
Non-operating profit	316	207	328	11	103.7%	20	106.6%
Non-operating expenses	243	207	228	(15)	93.7%	20	109.8%
<b>Ordinary profit</b>	<b>6,347</b>	<b>8,100</b>	<b>12,100</b>	<b>5,752</b>	<b>190.6%</b>	<b>4,000</b>	<b>149.4%</b>
(Extraordinary profit & Losses)							
Extraordinary profit	0	1	76	76	16399.5%	75	6418.3%
Extraordinary losses	914	679	743	(170)	81.3%	64	109.5%
Profit before income taxes and others	5,433	7,421	11,433	5,999	210.4%	4,011	154.0%
Income taxes	1,601	2,394	3,598	1,996	224.6%	1,203	150.2%
<b>Net Income</b>	<b>3,831</b>	<b>5,027</b>	<b>7,834</b>	<b>4,002</b>	<b>204.5%</b>	<b>2,807</b>	<b>155.9%</b>
Net income (loss) attributable to non-controlling interests	11	27	34	22	292.0%	7	128.5%
<b>Net income attributable to owners of the parent</b>	<b>3,819</b>	<b>5,000</b>	<b>7,800</b>	<b>3,980</b>	<b>204.2%</b>	<b>2,800</b>	<b>156.0%</b>
Depreciation and amortization (Property, Plant and equipment and intangible assets)	2,921	3,305	3,236	315	110.8%	(68)	97.9%
Amortization of goodwill	496	486	486	(10)	97.9%	(0)	99.9%

※1 Net sales of research reagents include that of in vitro diagnostics, which have been sold in the third quarter of the fiscal year under review.

※2 Net sales of “Other” in the previous fiscal year were included in “Research reagents” from the fiscal year under review, and results for the previous fiscal year in this table have been reclassified to reflect this change.

※3 The disclosure of profit and loss by segment (operating profit) is omitted because the reporting segments were changed to a single segment from the current consolidated fiscal year.